REPROPARK

New experimental therapeutic approaches for Parkinson’s disease by direct DA neuronal reprogramming

Coordinatore	Ospedale San Raffaele    more Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.
Nazionalità Coordinatore	Italy [IT]
Totale costo	2˙415˙767 €
EC contributo	2˙415˙767 €
Programma	FP7-IDEAS-ERC Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	ERC-2013-ADG
Funding Scheme	ERC-AG
Anno di inizio	2014
Periodo (anno-mese-giorno)	2014-06-01   -   2019-05-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	FUNDACION PARA LA INVESTIGACION MEDICA APLICADA FIMA  Organization address address: AVENIDA DE PIO XII 55 city: PAMPLONA postcode: 31008 contact info Titolo: Mrs. Nome: Ana Cognome: Iglesias Garcia Email: send email Telefono: +34 948194700 Fax: +34 948194718	ES (PAMPLONA)	beneficiary	420˙500.00
2	Ospedale San Raffaele  Organization address address: Via Olgettina 60 city: Milano postcode: 20132 contact info Titolo: Dr. Nome: Maria Rosa Cognome: Pedrazzi Email: send email Telefono: +39 0226435480 Fax: +39 0226434717	IT (Milano)	hostInstitution	1˙995˙267.00
3	Ospedale San Raffaele  Organization address address: Via Olgettina 60 city: Milano postcode: 20132 contact info Titolo: Dr. Nome: Vania Cognome: Broccoli Email: send email Telefono: +39 0226434616 Fax: +39 0226436164	IT (Milano)	hostInstitution	1˙995˙267.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Neurodegenerative diseases cause a significant burden on the elderly population in Europe. Parkinson’s disease (PD) affects 1.2 million people in Europe and with the increasing life expectancy this number will rise, putting more pressure on health care. Treatment of PD is only symptomatic, and therefore, there is an urgent need for more efficient therapies. Degeneration of mesencephalic DA neurons triggers the initial phases of PD, which raises the concept that cell replacement might represent a long-term restorative option for this neuropathology. Indeed, previous studies in PD patients have indicated that cell therapy has the potential to significantly sustain an enduring symptomatic relief. However, these studies suffered for lacking an ideal source of transplantable human DA neurons. Only recently the generation of induced stem cells (iPSCs) by the reprogramming of somatic cells has disclosed the possibility to generate individual specific neurons with a high therapeutic potential. We have recently developed a methodology that promotes transdifferentiation of mouse and human fibroblasts into functional induced dopaminergic neuronal (iDAN) cells. iDAN cells display sophisticated neuronal properties including pacemaking firing activity, synaptic integration, activity-dependent dopamine release and D2 functional autoreceptors. Therefore, iDAN cells offer an unprecedented cellular source with ideal features for cell therapy in PD, since they can be generated from the patients in high amounts. Here, we propose to strengthen the technology in the human setting and decipher the molecular events. Next, we will elaborate methods of in vivo reprogramming promoting neuronal transdifferentiation locally in the mouse brain. Finally, autologous transplantations of iDAN cells in parkinsonian monkeys will be attempted. Overall, this project will enhance cell reprogramming technologies with the ambition to generate a superior cellular source for transplantations in PD patients.'